- Home
- TRNS vs CTNM Comparison
TRNS vs CTNM Comparison
Compare TRNS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRNS | CTNM |
|---|---|---|
| Founded | 1964 | 2009 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Electrical Products | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.9M | 507.0M |
| IPO Year | 1995 | 2024 |
Fundamental Metrics
Financial Performance| Metric | TRNS | CTNM |
|---|---|---|
| Price | $70.95 | $13.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $116.00 | $19.80 |
| AVG Volume (30 Days) | 144.1K | ★ 174.8K |
| Earning Date | 05-04-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $278,421,000.00 | N/A |
| Revenue This Year | $21.75 | N/A |
| Revenue Next Year | $7.55 | N/A |
| P/E Ratio | $191.53 | ★ N/A |
| Revenue Growth | ★ 7.30 | N/A |
| 52 Week Low | $50.23 | $3.35 |
| 52 Week High | $97.08 | $16.33 |
Technical Indicators
Market Signals| Indicator | TRNS | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 41.17 |
| Support Level | $71.05 | $10.17 |
| Resistance Level | $81.17 | $16.17 |
| Average True Range (ATR) | 3.16 | 0.98 |
| MACD | -1.32 | -0.36 |
| Stochastic Oscillator | 25.29 | 5.43 |
Price Performance
Historical ComparisonAbout TRNS Transcat Inc.
Transcat Inc is involved in providing calibration and laboratory instrument services and the distribution of test, measurement, and control instrumentation. The product and services portfolio of the company consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, and others. The firm has Service and Distribution operating segments. The company derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Extech, FLIR, Fluke, Keysight, Megger, and others.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.